The Board of Gavi, the Vaccine Alliance this week endorsed a series of adjustments to bring Gavi’s strategy for its next five-year period (2026-2030) in line ...

GSK is taking to the airwaves to get the message out about respiratory syncytial virus (RSV), presenting a TV special about how the pathogen has affected athletes in the upcoming National Senior Games ...

Despite strong clinical data, RSV immunization rates among pregnant women and older adults remain worryingly low, ...

The risk for respiratory syncytial virus-related hospitalizations is elevated in children with chronic medical conditions ...

A single shot during pregnancy is proving to be a powerful shield for newborns against one of the most common and dangerous viruses for infants: RSV. In a new UK study, babies whose mothers received t ...

The move targets thimerosal, a preservative that anti-vaccine activists blame for neurodevelopmental disorders, despite ...

The deal complements an existing partnership with Novavax that encompasses R&D of combination vaccines for Covid-19 and flu.

The new guidance on vaccines, such as those that protect against COVID-19, influenza, and RSV, will be released by the end of the summer, ahead of respiratory season.

Respiratory syncytial virus (RSV) poses a significant, often overlooked, risk for serious cardiovascular complications in ...

It’s not surprising that, of all the recommendations the U.S. CDC’s vaccine advisory board made at its June meeting, the first one Health and Human Services Secretary Robert Kennedy signed off on ...

The CDC recently updated RSV vaccine recommendations to include certain adults aged 50 and up. When is the best time to get ...

Sanofi acquires Vicebio for $1.15 billion, adding a next-gen RSV-hMPV vaccine and ‘Molecular Clamp' tech to strengthen its respiratory vaccine pipeline.